Trial size may limit use of Seattle Genetics drug
9:28 AM | Author: Inhiptwit36
WASHINGTON (Reuters) - U.S. drug reviewers might limit the use of a Seattle Genetics Inc experimental blood cancer drug due to the narrow scope of its clinical trials, sending the company's shares down 3.6 percent.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/mbs2wFAdX3c/us-seattlegenetics-idUSTRE76B6VO20110712

reuters entertainment feeds reuters environment feeds environment reuters environment feeds reuters healthnews

|
This entry was posted on 9:28 AM and is filed under . You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

0 comments:

Post a Comment